sb 203580 has been researched along with 24,25-dihydroxyvitamin d 3 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (24,25-dihydroxyvitamin d 3) | Trials (24,25-dihydroxyvitamin d 3) | Recent Studies (post-2010) (24,25-dihydroxyvitamin d 3) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 816 | 33 | 82 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akamatsu, S; Dohi, S; Hirose, H; Kozawa, O; Matsuno, H; Tanabe, K; Uematsu, T; Yamamoto, T | 1 |
1 other study(ies) available for sb 203580 and 24,25-dihydroxyvitamin d 3
| Article | Year |
|---|---|
1,25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase.
Topics: 24,25-Dihydroxyvitamin D 3; Animals; Aorta; Calcitriol; Cells, Cultured; Drug Interactions; Endothelial Growth Factors; Imidazoles; Lymphokines; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Rats; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |